Systematic Review and Recommendations to Combine Newer Therapies With Conventional Therapy in Psoriatic Disease

Sandeep Arora 1*, Pankaj Das 1 and Gulhima Arora 2

1 Department of Dermatology, Army College of Medical Sciences & Base Hospital Delhi Cantt, New Delhi, India, 2 Consultant Dermatologist, Mehektagul Dermaclinic, New Delhi, India

Background: Psoriasis continues to have unmet needs in its management despite introduction of newer molecules. Monotherapy with these newer agents may not achieve therapeutic goals in all cases, hence necessitating their combinations with other molecules. Improved understanding of newer as well as conventional treatment modalities and experiences in their combinations hence necessitates therapeutic guidelines for their use in psoriasis.

Objective: To review the combinations of treatments reported in literature and recommendations for their use based on best current evidence in literature.

Methods: A literature review of MEDLINE database for studies evaluating combinations of newer therapies with conventional therapies in psoriasis was done. Newer therapies were identified as biologic disease modifying anti rheumatic drugs and other molecules such as apremilast while conventional therapies included methotrexate, cyclosporine, or retinoids, phototherapy and others. The therapeutic guidelines are proposed with the aim to provide evidenced based approach to combine newer and conventional agents in day-to-day psoriasis management.

Findings: Combination of acitretin and narrow band ultraviolet B (NB-UVB)/Psoralen with ultraviolet A (PUVA) achieves faster clearance and allows reduction of dose of the latter. A variable outcome is reported of methotrexate with TNF-α inhibitors vs. TNF-α inhibitors alone, although addition of methotrexate appears to reduce immunogenicity of TNF-α inhibitors thereby preventing formation of anti-drug antibodies especially in case of infliximab. While combination of acitretin and PUVA is beneficial, combining TNF-α inhibitors and phototherapy too produces better and faster results but long term risks of Non Melanoma Skin Cancers (NMSCs) may preclude their use together. Combination of cyclosporine and phototherapy is not recommended due to greater chances of NMSCs. Adding phototherapy to Fumaric Acid Esters (FAEs) improves efficacy. Apremilast can be safely combined with available biologic agents in patients with plaque psoriasis or psoriatic arthritis not responding adequately to biologics alone. Hydroxyurea and acitretin may be used together increasing their efficacy and reducing doses of both and hence their adverse effects.
Psoriasis is a chronic relapsing-remitting inflammatory papulosquamous disease, which affects ~0.51–11.43% of adults worldwide (1). This immune-mediated disease causes chronic inflammation in milieu which not only affects skin, but also joints, blood vessels, heart, liver, and kidneys (2) as well as metabolic syndrome (3, 4). PsA (Psoriatic Arthritis) may be present in > 40% of psoriasis patients leading to joint damage and deformities thereby severely affecting QoL (Quality of Life) and physical functioning (5−7). Early diagnosis and treatment intervention are crucial for optimal patient care (8, 9). The chronic relapsing course of disease with these co-morbidities are associated with increased physical and psychological burden, which leads to impaired Quality of Life (QoL) and depression (10). Mild psoriasis responds to topical therapy while moderate to severe psoriasis may need augmentation with phototherapy or systemic agents. Severe psoriasis may sometimes be refractory to one systemic agents requiring combination with another to maintain remission (11, 12). Combining therapeutic agents holds potential in synergistic action for a better control over disease activity. Moreover, a combination may be needed to reduce adverse effects by allowing reduction of dose despite severe disease. However, combining therapies pose challenges in tolerability, acute and long-term adverse effects in the absence of clear overall guidelines. Conventionally, immunosuppressive and non-biologic disease modifying immune-modulatory drugs such as methotrexate, cyclosporine, retinoids, phototherapy, and others have been used. Management of psoriasis has been revolutionized by biologics which have improved management of psoriasis but aren’t panaceas either. Combining newer and conventional therapies provide a tantalizing option for managing psoriasis, to achieve prolonged remission and better Quality of Life (QoL). Although there are numerous Randomized Controlled Trials (RCTs), case series, case reports, and expert opinions proving efficacy of different combinations in various clinical scenarios, literature is lacking in clear cut guidelines on how and when to combine the newer and conventional therapeutic options. This review aims at analyzing data available from studies with highest quality of evidence i.e., RCTs and generate recommendations for combining newer and conventional therapies in psoriatic disease.

INTRODUCTION

MATERIALS AND METHODS

Protocol Development and Eligibility Criteria
A protocol was designed and followed as laid down by PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analyses) statement (Figure 1). The conventional therapies considered being immunosuppressive and non-biologic disease modifying immune-modulatory drugs such as methotrexate, cyclosporine, retinoids, phototherapy, hydroxyurea, and fumaric acid esters (13). The newer therapies were identified as biologic disease modifying anti-rheumatic drugs namely- TNFα (Tumor Necrosis Factor-α) inhibitors- etanercept, adalimumab, infliximab, golimumab, and certolizumab pegol; IL-17A (Interleukin-17A) inhibitors- secukinumab and ixekizumab; IL-17RA (Interleukin-17 Receptor Antagonist)- brodalumab; IL-12/IL-23 inhibitor- ustekinumab, IL-23 inhibitor- guselkumab; oral PDE-4 (Phosphodiesterase-4) inhibitor- apremilast and tofacitinib selective JAK (Janus Kinase) 1 and 3 inhibitor (14).

Search Strategy
A literature search was performed for studies conducted in psoriasis therapeutics published before 01 Jan 2021. MEDLINE (OVID, from 1948), EMBASE (OVID, from 1980), Cochrane Central Register of Controlled Trials (CENTRAL), ahead of print subset fraction from Pubmed - not yet published in (OVID MEDLINE), and ongoing trial registries (http://clinicaltrials.gov/) were searched with no language restrictions. The search included the following in the keywords: “methotrexate” OR “cyclosporine” OR “ciclosporine” OR “acitretin” OR “phototherapy” OR “hydroxyurea” OR “fumaric acid esters” OR “conventional” [MeSH term] OR “drugs” [MeSH term] OR “etanercept” OR “infliximab” OR “adalimumab” OR “secukinumab” OR “golimumab” OR “ixekizumab” OR “ustekinumab” OR “guselkumab” OR “certolizumab pegol” OR “apremilast” OR “tofacitinib” OR “biologics” [MeSH term] OR “psoriasis” [MeSH term] OR “combination” [MeSH term] OR “therapy” [MeSH term].

Conclusion: Selected clinical scenarios shall benefit from combinations therapies, improving efficacy of both conventional and newer agents and at the same time helping reduce toxicity of higher dosages when used individually.

Keywords: psoriasis, combination (combined) therapy, conventional therapy, biologics, guidelines and recommendations

Search Terms

The search terms which were used are as follows: (“methotrexate” OR “cyclosporine” OR “ciclosporine” OR “acitretin” OR “phototherapy” OR “hydroxyurea” OR “fumaric acid esters” OR “conventional” [MeSH term] OR “drugs” [MeSH term] OR “etanercept” OR “infliximab” OR “adalimumab” OR “secukinumab” OR “golimumab” OR “ixekizumab” OR “ustekinumab” OR “guselkumab” OR “certolizumab pegol” OR “apremilast” OR “tofacitinib” OR “biologics” [MeSH term] OR “psoriasis” [MeSH term] OR “combination” [MeSH term] OR “therapy” [MeSH term]).
FIGURE 1 | PRISMA flow diagram for selection of studies.
Inclusion Criteria
Randomized Controlled Trials (N > 10) which reported on the efficacy and safety of combined use of conventional and newer drugs in psoriatic disease were included. Potential combinations in which RCTs have not been carried out, studies with lower levels of evidence were also included.

Exclusion Criteria
In-vitro, preclinical and animal studies, case reports and expert opinions were excluded from the review as well as studies not meeting the inclusion criteria. Studies with rotational or sequential therapies using these drugs as well as those combining alternative medicines (i.e., Chinese herbal) were excluded. Biosimilars were excluded from the study to maintain uniformity on drug efficacy data.

Selection of Studies
Using the above keywords, the titles and abstracts from electronic literature search were screened, and full text of articles that met the pre-defined inclusion criteria were obtained. Successively, articles were scanned for inclusion or exclusion. The selection of studies were implemented by 2 reviewers independent of each other (S.A. and P.D.). The quality of each included articles was assessed in agreement with the Cochrane handbook of systematic reviews of interventions 5.1.0 (updated March 2011). Any disagreements between the two reviewers were resolved by commonly drawn consensus by discussion or intervention by a third reviewer (G.A.).

Data Extraction
Information on the year of publication, study design, study reference, number of patients (N), baseline disease severity, treatment schedule, duration of combination therapy, and period of follow-up were extracted. Critical as well as important outcomes were carefully chosen to determine the quality of evidence. Critical outcomes were defined as the proportion of patients who attained a PASI (Psoriasis Area and Severity Index) of 90, PASI of 75, and a PGA (Physician Global Assessment) of clear or almost clear; discontinuation of a particular drug because of AEs (Adverse Effects); proportion of patients who encountered SAEs (Serious Adverse Events); and mean change in DLQI (Dermatology Life Quality Index). Important outcomes were defined as lack of efficacy leading to withdrawals (number), proportion of patients with AEs (not leading to drug withdrawal), mean time to clearance, mean change in PASI (0–72, 0–18, and 0–16) and mean time to relapse.

RESULTS
Our literature search yielded 25 RCTs (Table 1) combining different drugs which met the criteria to be included for analysis in the present study. Potential drug combinations for which RCTs have not been done, studies with lesser levels of evidence up to case series were searched for to look for evidence and gaps in research (Table 2).

Discussion and Recommendations
Literature search yielded 25 RCTs combining different agents to treat psoriasis and/or psoriatic arthropathy. Most of the studies involved combinations with Narrow Band Ultraviolet B (NB-UVB) /Psoralen with Ultraviolet A (PUVA) or methotrexate.

NB-UVB/PUVA and Acitretin
There are 02 RCTs involving acitretin and UVB/PUVA by Tanew et al. (15) and Lowe et al. (16). The former found that the cumulative PUVA dose required for complete clearance in PUVA-acitretin group was 58.7 ± 17.9 J/cm² whereas in PUVA-placebo group was 101.5 ± 15.8 J/cm². In RCT by Lowe et al. (16), 14 participants in the UVB-acitretin group took a total of 873 min of UVB exposure for complete clearance as compared to a significantly higher time- 1,236 min in the UVB-placebo group (n = 15). At the end of 12 weeks, the mean PASI ± SD in acitretin + UVB group reduced significantly from 8.83 ± 1.8 to 2.27 ± 1.04 (p < 0.01), whereas it reduced from 9.75 ± 2.34 to 6.36 ± 3.07 in placebo + UVB group. Both the RCTs concluded that adding UVB/PUVA to acitretin achieves greater as well as faster clearance than either placebo- UVB/PUVA or acitretin alone. Clinical adverse effects of added acitretin in both the studies were generally well-tolerated and similar to previous studies in treatment of psoriasis with acitretin (46–48).

Recommendation
We recommend combining these two modalities when patients do not respond to either one of the two. In addition to increased efficacy, the combination allows reduction of cumulative dose of UVB/PUVA. Also important is the prevention of non-melanoma skin cancers by acitretin which may be caused by long term UVB/PUVA (49, 50).

NB-UVB With TNFα Inhibitors
Etanercept with NB-UVB combination has been evaluated by Lynde et al. (17), Park et al. (18), Calzavara-Pinton et al. (19), and Gambichler et al. (20). Lynde et al. (17) concluded that addition of NB-UVB to etanercept did not significantly improve the overall clinical response except for a subset of patients with high adherence to NB-UVB without increasing the adverse effects significantly. Park et al. (18) studied combination of etanercept and NB-UVB in obese patients. They concluded that the combination has a similar efficacy to etanercept monotherapy even in the setting of obesity. However, Calzavara-Pinton et al. (19) who performed an intra-individual RCT in receiving etanercept and a randomized half of the body with NB-UVB for found that The PSI (Psoriasis Severity Index) scores of non-irradiated control lesions were 6.4 ± 2.3 and 5.8 ± 2.5 (p = not significant) before and after the treatment respectively, whereas the PSI of irradiated psoriatic plaques were 6.3 ± 2.3 and 0.5 ± 0.8 (p < 0.05). In the combination group, the mean PASI ± SD value reduced from 16.2 ± 9.2 to 2.4 ± 2.8 in 12 weeks. The patients received 14.6 ± 3.3 exposures resulting in a cumulative dose of 8.4 ± 4.2 J cm⁻². While the combined treatment was always well-tolerated, it was aimed at short duration of NB-UVB therapy for faster clearance to avoid long term adverse effects. It also may help reduce total doses as well as cost of...
| S no. | References | Study design | No of patients | Baseline disease severity | Intervention | Control group(s) | Study length (weeks) | Follow up (weeks) | Outcome measures used in study analysis | LoE |
|-------|------------|--------------|----------------|---------------------------|--------------|------------------|---------------------|-------------------|----------------------------------------|-----|
| 1.    | Tanew et al. (15) | Randomized double blinded trial | 60 | ≥20% BSA or PASI ≥10 | Acitretin 1 mg per kg per day plus four PUVA exposures per week | Placebo plus four PUVA exposures per week | Until complete clearance/maximum of 11 weeks. | 11 | Complete remission or marked improvement i.e. at least 90% clearing of psoriasis | 2b |
| 2.    | Lowe et al. (16) | Randomized controlled trial | 37 | Moderate to severe chronic plaque type psoriasis | Acitretin 50 mg per day plus UVB | Placebo plus UVB | 12 | 12 | Mean PASI at the end of 12 weeks | 2b |
| 3.    | Lynde et al. (17) | Single- blinded randomized controlled trial | 99 | ≥10% BSA or PASI ≥10 | Etanercept 50 mg once a week plus thrice weekly NB-UVB | Etanercept 50 mg once a week | 24 | 24 | PASI 90, PASI 75, PGA- clear, minimal, mild, moderate, severe, very severe BSA and DLQI (i) PASI 75 response after 12 weeks of combination etanercept and NB-UVB therapy (ii) Improvement in average PASI, (iii) Improvement in BSA and (iv) Improvement in PGA | 1b |
| 4.    | Park et al. (18) | Randomized, 'head-to-head' pilot trial | 30 | ≥10% BSA or PASI ≥10 with BMI of 30 or greater | Etanercept induction dose at 50 mg twice weekly for 12 weeks followed by combination of etanercept at maintenance dose of 50 mg weekly with NB-UVB thrice weekly | Etanercept induction dose at 50 mg twice weekly for 12 weeks followed by etanercept monotherapy at maintenance dose of 50 mg weekly | 24 | 24 | (i) PASI 75 response after 12 weeks of combination etanercept and NB-UVB therapy (ii) Improvement in average PASI, (iii) Improvement in BSA and (iv) Improvement in PGA | 1b |
| 5.    | Calzavara-Pinton et al. (19) | Randomized controlled intra-individual trial | 20 | PASI ≥10, Patients on etanercept alone who did not achieve PASI 75 within 12 weeks | Etanercept at 50 mg twice weekly plus NB-UVB thrice weekly on a selected psoriatic plaque | Covered plaque served as non-irradiated control | 24 | 24 | Mean PASI reduction, PASI 90, PASI 75 | 2b |
| 6.    | Gambichler et al. (20) | Randomized controlled intra-individual trial | 14 | PASI ≥10 | Etanercept at 50 mg twice weekly plus NB-UVB thrice weekly on a selected psoriatic plaque | Covered plaque served as non-irradiated control | 6 | 6 | Modified PASI reduction, performance of skin biopsies | 2b |
| 7.    | Wolf et al. (21) | Open-label randomized trial | 10 | PASI ≥10 | Ustekinumab at 45 or 90 mg at week 0 and 4 and plus NB- thrice weekly | Ustekinumab at 45 or 90 mg at week 0 and 4 | 6 | 12 | PASI of 75, mean change in PASI | 2b |
| 8.    | Mahajan et al. (22) | Randomized, single blinded, placebo controlled trial | 40 | ≥10% BSA | Methotrexate at 0.5 mg per kg once weekly to a maximum of 30 mg per week plus NB-UVB thrice weekly | Placebo plus NB-UVB thrice weekly | 24 | 24 | PASI 75, PASI 50 | 2b |
| 9.    | Asawananonda et al. (23) | Open-label randomized trial | 24 | ≥30% BSA | Methotrexate at 15 mg per week plus NB-UVB thrice weekly | Placebo plus NB-UVB thrice weekly | 24 | 24 | PASI 90, PASI 50, Dermatology Life Quality Index (DLQI) | 1b |
| 10.   | Al-Hamamy et al. (24) | Open-label randomized trial | 120 | ≥10% BSA | Methotrexate at 0.2 mg per kg weekly with a maximum of 20 mg per week plus NB-UVB thrice weekly | (i) Methotrexate at 0.2 mg per kg weekly with a maximum of 20 mg per week (ii) NB-UVB thrice weekly | 24 | 48 | PASI 90, PASI 50 | 2b |
| 11.   | Zachariae et al. (25) | Open-label randomized trial | 60 | ≥10% BSA or PASI ≥8 | Etanercept 50mg twice weekly for 12 weeks and then 25mg twice weekly for 12 weeks plus continued methotrexate therapy | Etanercept 50mg twice weekly for 12 weeks, and then 25mg twice weekly for 12 weeks plus methotrexate tapered and discontinued during the 4 weeks | 24 | 24 | Physician's Global Assessment (PGA), PASI 50, PASI 90, DLQI | 2b |

(Continued)
| S no. | References | Study design | No of patients | Baseline disease severity | Intervention | Control group(s) | Study length (weeks) | Follow up (weeks) | Outcome measures used in study analysis | LoE |
|-------|------------|--------------|----------------|--------------------------|--------------|-----------------|---------------------|------------------|-----------------------------------------|-----|
| 12.   | Gottlieb et al. (26) | Randomized, double-blind, placebo-controlled trial | 478 | ≥10% BSA or PASI ≥10 | Etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for 12 weeks plus methotrexate titrated from 7.5 mg to maximum of 15 mg or tolerated dose. | Etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for 12 weeks plus placebo | 24 | 24 | PASI 90, PASI 75, PASI 50, static Physician’s Global Assessment (sPGA), BSA improvement from baseline at weeks 12 and 24. Assessments were performed at screening, at baseline, and every 4 weeks thereafter throughout the study. | 1b  |
| 13.   | Yu et al. (27) | Randomized trial, unclear blinding | 30 | PASI ≥10 | Etanercept 50 mg once weekly plus oral methotrexate 7.5-15 mg per week | Etanercept 50 mg once weekly | 24 | 24 | PASI score, static Physician’s Global Assessment (sPGA), Patient’s Global Assessment (PtGA), Dermatology Life Quality Index (DLQI). | 2b  |
| 14.   | Mease et al. (28) | Randomized, double-blind, placebo-controlled triple-armed trial | 851 | 3 tender joints and 3 swollen joints (based on 68- and 66-joint, and an active psoriatic skin lesion that was ≥2 cm in diameter). | Etanercept (target dose 50 mg) plus oral methotrexate (target dose 20 mg) given weekly. | Methotrexate (target dose 20 mg) plus subcutaneous placebo given weekly or subcutaneous etanercept (target dose 50 mg) plus oral placebo given weekly. | 48 | 48 | ACR20, Minimal Disease Activity (MDA) response, Leeds Dactylitis Index (LDI), static Physician’s Global Assessment (sPGA). | 1b  |
| 15.   | Bananauskaitė et al. (29) | Open-label randomized trial | 115 | Psoriasis and psoriatic arthropathy | Infliximab 5 mg per kg infusions at weeks 0, 2, 6, and 14 plus methotrexate 15 mg per week | Methotrexate 15 mg per week | 16 | 16 | ACR20, ACR50 and ACR70 responses, PASI 75, PASI 90, EULAR response, physician and patient global assessment of disease activity, disease activity score in 28 joints (DAS28) scores, minimal disease activity (MDA) Disease Activity Score (DAS), MDA, ACR20/50/70 responses, Leeds Enthesitis Index, and Dermatology Life Quality Index (DLQI). | 2b  |
| 16.   | van Mens et al. (30) | Randomized, double-blind, placebo-controlled trial | 59 | Patients meeting CASPAR criteria and current active disease, defined as the presence of at least three swollen and three tender joints. | Methotrexate 25 mg per week or as tolerated plus Golimumab 50 mg administered every 4 weeks | Methotrexate 25 mg per week or as tolerated plus placebo prefilled syringes administered every 4 weeks | 22 | 22 | Disease Activity Score (DAS), MDA, ACR20/50/70 responses, Leeds Enthesitis Index, and Dermatology Life Quality Index (DLQI). | 2b  |
| 17.   | Vieira-Sousa et al. (31) | Randomized, double-blind, placebo-controlled trial | 48 | Classification for Psoriatic Arthritis criteria ≥1 digit with tender dactylitis and ≥1 other site of active inflammation (joints, enthesis, spine, skin, or nails). | Methotrexate 25 mg per week or as tolerated plus Golimumab 50 mg administered every 4 weeks | Methotrexate 25 mg per week or as tolerated plus placebo prefilled syringes administered every 4 weeks | 24 | 24 | Dactylitis Severity Score (DSS) DSS20, 50 or 70, Leeds Dactylitis Index (LDI), DLI20, 50 or 70, Enthesitis Index (LEI). | 2b  |
| 18.   | Lee et al. (32) | Randomized, open labeled trial | 60 | ≥10% BSA or PASI ≥10 | Etanercept 25 mg biweekly plus acitretin 10 mg twice daily for 24 weeks | Etanercept 25 mg biweekly for 12 weeks followed by etanercept 25 mg biweekly for 12 weeks. | 24 | 24 | PASI 75, PASI 50, clear/almost-clear by PGA | 2b  |

(Continued)
### TABLE 1 Continued

| S no. | References | Study design | No of patients | Baseline disease severity | Intervention | Control group(s) | Study length (weeks) | Follow up (weeks) | Outcome measures used in study analysis | LoE |
|-------|------------|--------------|----------------|---------------------------|--------------|------------------|---------------------|-------------------|------------------------------------------|-----|
| 19. Gisondi et al. | Randomized, controlled, investigator-blinded pilot trial | 60 | ≥ 10% BSA or PASI ≥ 10 | Etanercept 25 mg once weekly plus oral acitretin 0.4 mg per kg per day daily. | Etanercept 25 mg twice weekly subcutaneously; (ii) Acitretin 0.4 mg per kg per day daily in a single oral dose; and | 24 | 24 | PASI 75, PASI 50 and mean BSA reduction at week 24 | 2b |
| 20. van Bezooijen et al. | Randomized controlled trial | 33 | PASI ≥ 10 | Oral fumarates up to $4 \times 215$ mg plus Etanercept $2 \times 50$ mg/week for 12 weeks followed by $1 \times 50$ mg weekly from week 12 onwards | Etanercept at $2 \times 50$ mg/week for 12 weeks followed by etanercept to $1 \times 50$ mg weekly from week 12 onwards | 48 | 48 | PASI 75, PGA clear or almost clear | 2b |
| 21. Tzaneva et al. | Open-label randomized trial | 30 | ≥ 10% BSA or PASI ≥ 10 | Accelerated FAE dosing scheme with NB-UVB thrice weekly | Accelerated FAE | 26 | 26 | Mean PASI reduction, PASI 75, | 2b |
| 22. Phystowski et al. | Randomized, single blinded, placebo-controlled trial | 19 | >20% BSA | Calcitriol 0.5–2.0 µg per day plus NB-UVB four times weekly | Placebo plus NB-UVB | 5 | NR | Mean change in PASI (scale, 0–16) | 2b |
| 23. Ezquerra et al. | Open-label randomized trial | 40 | PASI ≥ 15 | Acitretin at 25 mg per day plus calcitriol 0.25 µg per day | Acitretin at 25 mg per day | 12 | NR | Mean change in PASI | 2b |
| 24. Mittal et al. | Randomized, double-blind, placebo-controlled trial | 41 | >20% BSA | Acitretin at 25 mg per day plus pioglitazone, Hydrochloride at 15 mg per day | Acitretin at 25 mg per day plus placebo | 12 | 12 | PASI 75, PGA of clear or almost clear, mean change in PASI, withdrawal because of lack of efficacy | 2b |
| 25. el-Mofty et al. | Randomized trial, unclear masking | 16 | ≥25% BSA | Sulfasalazine, 2 gms per day plus Pentoxifyline 1,200 mg per day | Methotrexate, 25 mg per week | 8 | NR | Mean change in PASI, Withdrawal because of lack of efficacy | 2b |

PUVA, Psoralen and Ultra Violet A; UVB, Ultra Violet B; NB-UVB, Narrow Band Ultra Violet B; BSA, Body Surface Area; PASI, Psoriasis Area and Severity Index; AE, Adverse Events; SAE, Serious Adverse Events; BMI, Body Mass Index; DLQI, Dermatology Life Quality Index; PGA, Physician’s Global Assessment; sPGA, static Physician’s Global Assessment; PtGA, Patient’s Global Assessment; ACR 20/50/70, American College of Rheumatology 20/50/70; MDA response, Minimal Disease Activity response; LDA 20/50/70, Leeds Dactylitis Index 20/50/70; EULAR response, European League Against Rheumatism response; DAS28 scores, Disease Activity Score in 28 joints; LSI, Leeds Enthesitis Index.
etanercept therapy. Calzavara-Pinton et al. (19) inferred that the combination is more effective than each therapy alone in the treatment of moderate-to-severe plaque psoriasis, and is well-tolerated. In an intra-individual RCT by Gambichler et al. (20) (n = 14) the relative M-PASI (modified-PASI) reduction of etanercept alone treated sites after 6-weeks was 53.7 ± 36.9%, whereas etanercept plus NB-UVB combination treated sites resulted in a significantly higher relative M-PASI reduction of 64.7 ± 27.8% (P = 0.011, 95% CI −19 to −3%) concluding that etanercept combined with NB-UVB is more effective than etanercept monotherapy at 6 weeks. Similarly, in an another intra-individual RCT by Wolf et al. (40) consisting of 04 participants who were followed up for 06 weeks concluded that adding thrice weekly NB-UVB to 40 mg bi-weekly adalimumab reduced mean PASI from 14.8 to 2.0 on UV-irradiated body halves vs. 6.9 on non-irradiated body halves (95% confidence interval, 0.4–9.4) accelerating the clearance of psoriatic lesions with no significant adverse effects. Bagel (41) performed a 24-week single-arm open-label study in 20 adults with moderate to severe psoriasis who received bi-weekly adalimumab 40 mg and thrice weekly NB-UVB phototherapy for 12 weeks and followed up for another 12 weeks. The mean baseline scores of patients were 17.0 for PASI, 21.2 for BSA (Body Surface Area) and 3.5 for PGA (Physicians Global Assessment). At the end of treatment at week 12, 19 (95%) patients achieved PASI-75, 15 (75%) PASI-90 and 11 (55%) achieved PASI-100. Seventeen (85%) were clear or almost clear (PGA score = 1). Mean baseline PASI, BSA, and PGA scores improved by 95, 93, and 80%, respectively. Moreover, the improvement was sustained through the end of follow up period at week 24 without any serious adverse events. Although none of the studies combining TNFα blockers and NB-UVB reported any major adverse effects, concerns were shown regarding the long-term effects of combining TNFα blockers with NB-UVB-especially malignancy.

### Recommendation

As the implication of malignancy in treatment with TNF-α blockers alone or in combination with NB-UVB complex with levels of TNF-α having varied effects on tumoral growth, (51) we recommend to restrict this highly effective combination for short duration up to 24 weeks, to obtain a quicker response and to avoid long-term complications (52–54). European Academy of Dermatology and Venereology (EADV) guidelines on management of psoriasis mention that TNFα blockers and NB-UVB may or may not be combined and it is not as strict a contraindication as cyclosporine with NB-UVB (55).

### NB-UVB and IL12/23 Inhibitor

There is only a single intra-individual RCT combining injection ustekinumab at 45/90 mg 4 weeks apart and thrice weekly 311-nm UVB by Wolf et al. (21) in 10 patients. At baseline, the mean PASI was similar in both irradiated and unirradiated body halves (13.6 vs. 13.3). At 6 weeks, PASI was significantly lower on irradiated body halves (2.5 vs. 6.1), (95% confidence interval 1.3–5). PASI 75 was achieved significantly more often on UV-irradiated body halves than on un-irradiated ones [7/9 patients (78%) vs. 1/9 (11%)]. They concluded that treatment with NB-UVB accelerates the clearance of psoriatic lesions at week 6 as well as at week 12 in ustekinumab-treated patients without increase in incidence of severe adverse effects.

### Recommendation

No specific recommendation could be offered as there is limited review of this combination. However, in patients on ustekinumab with a poor response NB-UVB may be added as it has a good safety profile.

### NB-UVB and Methotrexate

03 studies combining methotrexate and NB-UVB met the criteria to be included in our review- Mahajan et al. (22), Asawanonda et al. (23), and Al-Hamamy et al. (24). Mahajan et al. (22) combined oral methotrexate at 0.5 mg/kg once weekly [maximum of 30 mg/week and thrice weekly NB-UVB and compared it with placebo plus NB-UVB for a duration of 12 weeks. PASI 75 was attained in 19/20 patients in the combination group versus 14/20 patients in NB-UVB plus placebo group (p = 0.04)]. PASI 75 was achieved in 7.57 ± 3.09 weeks (4–16) in the combination group and 11.42 ± 4.98 weeks (6–20) in NB-UVB + placebo group (p < 0.006). The mean number of NB-UVB sessions to which the patients were exposed were

---

### Table 2: Summary of levels of evidence and strength of recommendations.

| S. no. | Drug combinations                     | Highest levels of evidence on efficacy | Recommendations for combination on basis of evidence |
|--------|---------------------------------------|----------------------------------------|-----------------------------------------------------|
| 1      | UVB/PUVA + Acitretin (15, 16)         | 2b B                                  | C                                                   |
| 2      | Etanercept + NB-UVB (17–20)           | 1b, 2b A                              | A                                                   |
| 3      | Adalimumab + NB-UVB (40, 41)          | 2b, 4 B                               | B                                                   |
| 4      | Ustekinumab + NB-UVB (21)             | 2b B                                  | B                                                   |
| 5      | Methotrexate + NB-UVB (22–24)         | 1b, 2b A                              | A                                                   |
| 6      | Etanercept + Methotrexate (25–28)     | 1b, 2b A                              | C                                                   |
| 7      | Infliximab + Methotrexate (29)        | 2b B                                  | B                                                   |
| 8      | Golimumab + Methotrexite (30, 51)     | 2b B                                  | B                                                   |
| 9      | Etanercept + Acitretin (32, 33)       | 2b B                                  | B                                                   |
| 10     | Apremilast + NB-UVB (42)              | 4 C                                   | C                                                   |
| 11     | Apremilast + Secukinumab (43, 44)     | 4 C                                   | C                                                   |
| 12     | Etanercept + Fumarates (34)           | 2b B                                  | B                                                   |
| 13     | Fumarates + NB-UVB (53)               | 2b B                                  | B                                                   |
| 14     | Calcitriol (oral) + Acitretin (57)    | 2b B                                  | B                                                   |
| 15     | Hydroxyurea + Acitretin (45)          | 4 C                                   | C                                                   |

Levels of evidence: 1a, Systematic review of (homogeneous) RCTs; 1b, Individual RCTs (with narrow confidence intervals); 2a, Systematic review of (homogeneous) cohort studies of “exposed” and “unexposed” subjects; 2b, Individual cohort study/low-quality RCTs; 3a, Systematic review of (homogeneous) case-control studies; 3b, Individual case-control studies; 4, Case series; low-quality cohort or case-control studies; 5, Expert opinions based on non-systematic reviews of results or mechanistic studies.

Strength of recommendations: A, Good evidence to support a recommendation for use; B, Moderate evidence to support a recommendation for use; C, Poor evidence to support a recommendation.
17.47 ± 6.62 (10–35) in the combination group and 35.72 ± 17.05 (16–6) in NB-UVB + placebo group \( (p < 0.0001) \). Mean NBUVB dose for achieving PASI 75 was 9.14 ± 5.39 J/cm\(^2\) (3.34–20.84) in the combination group as compared with 25.99 ± 18.55 J/cm\(^2\) in NB-UVB + placebo group \( (p < 0.001) \). Asawanonda et al. (23) showed that the median time to clear psoriasis in the former group was 4 weeks, which was significantly less than that of the latter. Ten of 11 patients on combination of methotrexate and NBUVB achieved PASI 90 compared with only 5/13 in the placebo/ NB-UVB group \( (p < 0.0001) \). The mean cumulative dose in methotrexate/NB-UVB group was 26.92 ± 15.54 J/cm\(^2\), as compared to 59.25 ± 16.71 J/cm\(^2\) \( (p = 0.002) \) in the placebo/NBUVB group. Al-Hamamy et al. (24) compared the combination of methotrexate with NB-UVB, methotrexate alone and NB-UVB alone and found no statistically significant difference in the number of patients achieving PASI 90 between the three groups in six months of treatment. However, the mean number of weeks required for achieving clearance was 6.11 ± 1.28 weeks in combination group and 11.42 ± 2.36 weeks in NB-UVB group, while 20.87 ± 4.21 weeks in methotrexate group \( p < 0.0001 \). The mean number of NBUVB sessions to which the patients were exposed was 17.86 ± 3.74 in combination group and 33.51±6.90 in NB-UVB group \( (p < 0.0001) \). The mean total cumulative dose of NBUVB phototherapy for achieving clearance was 12.13 ± 4.02 J/cm\(^2\) in the combination group; compared with 34.48 ± 13.13 J/cm\(^2\) in NB-UVB group \( (p < 0.0001) \). All 03 RCTs combining methotrexate with NBUVB concluded that the mean time to achieve reduction in PASI 75 was significantly less in the combined group as against those treated only with NB-UVB and addition of methotrexate to NB-UVB rapidly clears psoriatic lesions without any significant adverse effects.

**Recommendation**

We recommend combining NB-UVB with methotrexate for faster clearance of lesions. However, either may be discontinued after achieving PASI 75 and the other continued for maintenance therapy the duration of which shall be dictated by the disease burden.

**TNF\(\alpha\) Inhibitors and Methotrexate**

The following RCTs combining TNF\(\alpha\) blockers with methotrexate met the inclusion criteria- Zachariae et al. (25), Gottlieb et al. (26), Yu et al. (27), Mease et al. (28), Baranauskaite et al. (29), van Mens et al. (30), and Vieira-Sousa et al. (31) who compared the combination of TNF\(\alpha\) blockers with methotrexate with either TNF\(\alpha\) blockers alone or methotrexate alone. Zachariae et al. (25) randomized 60 patients who were already on methotrexate for at least 03 months into two groups receiving etanercept-methotrexate combination and etanercept with tapering and stopping methotrexate and noted significantly more number of patients achieving PASI 75 as well as significantly lower mean PASI scores at both 12 and 24 weeks in the combination group compared with etanercept alone with similar AEs for both groups, an effect that was maintained until the end of the study. Gottlieb et al. (26) studied 478 patients combining weekly methotrexate to patients who were already on etanercept since 24 weeks to the treatment group against placebo in control group. The percentage of patients achieving PASI 75 was significantly higher at week 24 for the combination therapy group (77.3%) compared with the monotherapy group (60.3%; \( p < 0.0001 \)). Overall, 74.9% of patients in the combination group experienced AEs compared with 59.8% in the monotherapy group. Withdrawals due to AEs were infrequent in both groups [combination, \( n = 10 \) (4.2%); monotherapy, \( n = 6 \) (2.5%)], and none of the AEs leading to withdrawal was considered to be serious or infectious. They concluded that addition of methotrexate to etanercept was more effective than etanercept monotherapy in patients with moderate to severe plaque psoriasis with acceptable tolerability. Yu et al. (27) compared similar treatment arms as above but started administering the combination from baseline and followed up subjects for 24 weeks. They found no significant change in the PASI score from baseline to 24 weeks. However, both sPGA (static Physician’s Global Assessment) and PtGA (Patient’s Global Assessment) scores were significant \( (p < 0.05) \). Adverse effects were reported in 60% of patients in the combination group and in 33% in the monotherapy group. None of the adverse effects were serious enough to discontinue treatment. Mease et al. (28) performed a triple arm study consisting of 851 patients of psoriatic arthropathy randomized to oral methotrexate 20 mg plus placebo weekly, etanercept 50 mg plus placebo weekly, or etanercept 50 mg plus oral methotrexate 20 mg weekly. ACR20 (American College of Rheumatology 20) criteria and MDA (Minimal Disease Activity) responses at week 24 were significantly greater for etanercept monotherapy vs. methotrexate monotherapy (ACR20: 60.9 vs. 50.7% \( [p = 0.029] \); MDA: 35.9 vs. 22.9% \( [p = 0.005] \)) and for combination therapy vs. methotrexate monotherapy (ACR20: 65.0 vs. 50.7% \( [p = 0.005] \); MDA: 35.7 vs. 22.9% \( [p = 0.005] \)).

Many patients in this trial had a moderate to severe level of psoriasis as assessed by BSA (Body Surface Area). Results from the dermatologic endpoints showed that etanercept and methotrexate had good efficacy, with a suggestion that the combination arm had slightly greater efficacy than either of the monotherapy arms for improved BSA. They concluded that etanercept monotherapy and combination therapy showed greater efficacy than methotrexate monotherapy in ACR, MDA, and BSA responses and radiographic progression. However, combining methotrexate and etanercept did not improve etanercept efficacy in either PsA or psoriasis. Baranauskaite et al. (29) combined infliximab at 5 mg per kg infusions at 0, 2, 6, and 14 weeks and methotrexate at 15 mg per week vs. methotrexate alone for a period of 16 weeks. 86.3% of patients receiving combination and 66.7% of those receiving methotrexate alone achieved an ACR20 response \( (p < 0.02) \). While 97.1% of patients receiving infliximab plus methotrexate achieved PASI 75, the figure was 54.3% in patients receiving methotrexate alone \( (p < 0.0001) \). They demonstrated significantly greater ACR 20 response rates and PASI 75 improvement in the combination group and was generally well-tolerated. A double-blind RCT measuring end points in psoriatic arthritis by van Mens et al. (30) studied combination of methotrexate 15–25 mg per week and subcutaneous injections of golimumab at 50 mg per month with that of methotrexate and placebo and found that
Disease Activity Score (DAS) remission at week 22 was almost doubled (21/26; 81%) in methotrexate plus golimumab group vs. methotrexate alone (10/24; 42%) ($p = 0.004$). Also the patients belonging to the combination group reached an MDA (Minimal Disease Activity) in 21/26 (81%) vs. 7/24 (29%) in the methotrexate arm ($p < 0.001$). An ACR 20/50/70 response was achieved by, respectively, 85, 81, and 58% in the combination arm vs. 58, 33, and 13% in the methotrexate arm ($p = 0.039$, $p = 0.001$, and $p = 0.001$, respectively). The most frequent adverse effect was nausea and occurred in similar incidences in both treatment arms and considered to be treatment related but was not severe enough to discontinue treatment. Likewise, a double-blind RCT by Vieira-Sousa et al. (31) comparing similar doses of golimumab plus methotrexate vs. placebo plus methotrexate in dactylitis in psoriatic arthropathy concluded that the combination of golimumab and methotrexate was superior to methotrexate alone in reducing Dactylitis Severity Score (DSS) and Leeds Dactylitis Index (LDI) with comparable incidence of adverse effects between treatment arms. All patients had active dactylitis at baseline, with a median baseline DSS of 6 in both arms. The patients treated with golimumab/methotrexate exhibited significantly greater improvements by DSS at week 24 (median change of 5) relative to the placebo/methotrexate group (median change of 2) ($p = 0.026$), and as early as 12 weeks ($p = 0.004$). The proportion of DSS50 (Dactylitis Severity Score 50) and DSS70 (Dactylitis Severity Score 70) responders at week 24 were also significantly higher for patients treated with golimumab/methotrexate (DSS50: $p = 0.005$, DSS70: $p = 0.010$) Endpoints to measure cutaneous efficacy like PASI, BSA and skin-related quality of life (Dermatology Life Quality Index) improved in both groups at week 24 but difference in both treatment groups was not significant. 102 adverse events were reported during study period, with similar incidence between the treatment arms and mostly of mild to moderate severity. According to systematic review by Hsu et al. (56), there are 06 studies measuring anti-drug antibodies in etanercept and its possible effect on drug efficacy- they found the prevalence of anti-etanercept antibodies (AEA) ranging from 0 (57) to 18.3% (58) in psoriasis, and none of which had significant effect on treatment efficacy (56). Similarly, 10 studies proved prevalence of anti-infliximab antibodies (AIA) ranging from 5.4 (59) to 43.6% (60) with most of these studies showing significant decreased mean PASI scores and greater loss of clinical response when compared to AIA-negative patients (56). A study by Adisen et al. (61) with five patients of psoriasis who developed AIA, determined that AIA positivity disappeared after 8 weeks of combined methotrexate pulse therapy, ranging from 5 to 15 mg/week. Six studies assessed for Anti-Ustekinumab Antibody (AUA) formation in patients with moderate-to-severe psoriasis showed ranges from 3.8 (62) to 5.4% (63) in psoriasis (56). But their clinical significance on treatment response is yet to be evaluated (56).

**Recommendation**

We recommend combining TNFα blockers with methotrexate in moderate to severe psoriatic disease especially while using infliximab. Poor response to etanercept alone at lower doses as elaborated below necessitates an additional drug, methotrexate being a good option.

**TNFα Inhibitors With Cyclosporine**

Atzeni et al. (64) who performed an RCT comparing etanercept plus cyclosporin with etanercept plus methotrexate show similar efficacy in reducing DAS28 (Disease Activity Score 28) in patients with moderate/severe psoriatic arthropathy and peripheral arthritis, but former combination was more efficacious in reducing psoriatic skin involvement. PASI 50 and PASI 75 scores were achieved by 88 and 53%, respectively, in the patients in etanercept plus cyclosporin group, and 73 and 32%, respectively, in the patients in etanercept plus methotrexate group ($p < 0.05$). There was no significant difference in serious adverse events between the two treatment groups.

**Recommendation**

We recommend TNFα blockers with cyclosporine in moderate to severe psoriasis with arthropathy for rapid remission, however side effects limit the duration of treatment with cyclosporine and sequential therapy with methotrexate is recommended.

**TNFα Inhibitors With Acitretin**

Lee et al. (32) randomized 60 subjects into three treatment arms- ETN-ETN (etanercept- etanercept), ETN-ACT (etanercept-acitretin), and ACT (acitretin). The median time to achieve PASI 75 for patients in the ETN–ETN arm was 126 days vs. 146 days for patients in the ETN-ACT arm. The median time to achieve PASI 50 was same in ETN–ETN and ETN-ACT arms (56 days) and much shorter than for patients in ACT arm (126 days). The difference was statistically significant among the three treatment arms (PASI 75: $p = 0.0448$ and PASI 50: $p = 0.0033$). Lee et al. (32) proved that the combination is more effective than acitretin alone without increase in adverse effects. In another study with similar treatment arms Gisondi et al. (33) randomized 60 patients into three groups to receive etanercept 25 mg twice weekly; acitretin 0.4 mg per kg daily; and etanercept 25 mg once weekly plus oral acitretin 0.4 mg per kg daily. PASI 75 response at week 24, was achieved by 10 of 22 patients (45%) in the etanercept group, six of 20 (30%) in the acitretin group and eight of 18 (44%) patients with etanercept plus acitretin group ($P = 0.001$ for both etanercept groups compared with acitretin alone). PASI 50 response at week 24 too showed similar significant results ($P = 0.001$ for both etanercept groups compared with acitretin alone).

**Recommendation**

Etanercept 25 mg twice weekly with acitretin is a superior option to acitretin alone. We recommend addition of acitretin to etanercept dose of 25 mg twice weekly before considering a higher dose of etanercept 50 mg twice weekly.

**Apremilast Combinations**

Apremilast, a PDE4 inhibitor has minimal immunosuppressive effects when compared to biologics. There are no RCTs combining apremilast with any other drug. However, case series and retrospective studies have suggested that combination of apremilast with other drugs and biologics like methotrexate,
acitretin, cyclosporin, secukinumab, etanercept, adalimumab, ixekizumab, and ustekinumab have been effective, look promising and may be exercised to reduce adverse effects of either of two.

In an open-labeled prospective study combining apremilast 30 mg twice daily and increasing doses of NB-UVB three times per week for 12 weeks. 73% (16 of 22 completers) achieved a PASI 75 response at week 12. The most commonly reported adverse events were mild and moderate first-degree burns related to NB-UVB (n=11 [38%] patients). Bagel et al. (42) concluded that the combination provided a new treatment option without any increased adverse effects. Both Sacchelli et al. (43) and De et al. (44) published case series and case reports combining apremilast with secukinumab and found improvement in PASI scores. Metyas et al. (65) and Takamura et al. (66) performed retrospective studies reporting the efficacy of apremilast in combination with any other biologics and inferred that apremilast can be safely combined with all biologic agents in patients with plaque psoriasis or psoriatic arthritis not responding adequately to biologics alone. Another retrospective study by AbuHilal et al. (67) studied the combination of apremilast with other biologics as well as conventional drugs like methotrexate, acitretin, cyclosporine with similar conclusion.

**Recommendation**

We recommend apremilast 30 mg twice daily and NB-UVB as a combination modality not responding or minimally responding to either of the two. The combination of apremilast and a biologic may be a safe, useful treatment option for managing patients with psoriasis showing biologic fatigue, but not as a routine. However, large scale studies with higher level of evidence like RCTs are needed in future.

**Miscellaneous Combination Therapies**

RCTs combining less used unconventional drugs in psoriasis included in this review dealt with fumaric acid esters (FAEs) calcitriol, sulfasalazine, pentoxifylline, and pioglitazone with conventional modes of therapy. An exploratory RCT by Bezoojien et al. (34) combining etanercept 50 mg twice weekly for 12 weeks followed by once weekly for another 12 weeks with oral fumarates 215 mg four times daily for the whole period vs. etanercept alone found out that the reduction in PASI score per week for the combination therapy was 5.97% (95% confidence interval, CI: 5.08–6.85) and in the monotherapy group 4.76% (95% CI: 3.57–5.93; p = 0.11). They concluded that combination therapy caused quicker improvement in PASI 75 in first 24 weeks although difference in the PASI score between the two groups was statistically insignificant but with satisfactory tolerability. In another RCT by Tzaneva et al. (35), an increasing dose of FAEs was combined with NB-UVB. At 26 weeks of treatment, the median baseline PASI of 15.4 [interquartile range (IQR) 11.7–21.0] was reduced to 2.8 (IQR 1.6–4.8) in the combination group and from 14.0 (IQR 12.5–15.1) to 9.0 (IQR 6.5–12.1) in the FAE group, respectively. The mean absolute and relative reduction in PASI was significantly greater in the combination group (10 and 69%) compared with patients receiving only FAE (5 and 36%) (p = 0.016). Side-effects related to FAE were mainly mild gastrointestinal complaints reported by 12/16 patients (75%) in the monotherapy group and 3/14 patients (21%) in the combination group. These were abdominal pain, nausea, flatulence, diarrhea that occurred at the beginning of treatment, were dose-dependent and improved after a temporary dose reduction. They found an accelerated as well as augmented response improving the quality of life in the patients with combination therapy as compared with fumaric acid esters monotherapy with no increase in adverse effects in the combination group.

A single blinded, placebo-controlled trial combining calcitriol 0.5–2.0 µg per day plus NB-UVB against NB-UVB alone by Prystowsky et al. (36) concluded that there was no added benefit to treatment when oral calcitriol was administered with phototherapy. Our search yielded only a single RCT combining acitretin and calcitriol- Ezquerra et al. (37) who compared the combination with acitretin alone. Initial PASI of 26.90 reduced to 13.3 in acitretin alone group; whereas it reduced from 28.35 to 10.3 in acitretin+calcitriol combination group which was statistically significant (p < 0.05). A double-blind RCT by Mittal et al. (38) compared combination of acitretin plus pioglitazone hydrochloride with acitretin alone. The percentage of reduction in the PASI score from baseline to 12 weeks of treatment was 64.2% (95% CI, 49.2–79.3%) in the combination group compared with 51.7% (95% CI, 38.7–64.7%) in the acitretin plus placebo group (p = 0.04). The adverse effects in both the groups were mild to moderate and were comparable. el-Mofty et al. (39) conducted a quadri-armed RCT comparing the combination of sulfasalazine and pentoxifylline to methotrexate alone (active control group), sulfasalazine alone and pentoxifylline alone and concluded that combination of sulfasalazine and pentoxifylline though effective than when used alone, is not as effective as methotrexate, may be promising and tried because they present as safer and well-tolerated alternatives to methotrexate. There are no RCTs on hydroxyurea in psoriasis. Hydroxyurea becomes one of the drugs of choice in settings of psoriasis in HIV, where not only it helps in controlling psoriasis, but also in controlling viral loads especially when combined with didanosine (NRTI) (68, 69).

In a retrospective study, Narang et al. (45) combined lower doses of hydroxyurea 1 g daily with acitretin 25 mg daily for the management of refractory cases and found them to be superior to either to hydroxyurea and acitretin alone as found in previous studies. Combining acitretin with hydroxyurea may theoretically reduce the risk of non-melanoma skin cancers and actinic keratosis, which are rare but serious adverse effect of hydroxyurea (49, 70). Methotrexate too have been combined with hydroxyurea in lower doses (5–10 mg/week and 500 mg per day, respectively) to good effect with no increase in adverse effects of either of the two (71). Though theoretically both the drugs may cause GI intolerance and myelosuppression, they were not found in the study.

**Recommendation**

We recommend combining hydroxyurea and acitretin in recalcitrant cases of psoriasis not responding to conventional stand-alone drugs. This combination also may be used in HIV
where both the drugs do not cause immune suppression with added benefit of anti-viral action of hydroxyurea.

Combining methotrexate with hydroxyurea in lower doses may help reducing dose-dependent or cumulative toxic effects of either of the two.

Our search for combinations comprising relatively newer drugs like guselkumab, tildrakizumab, certolizumab pegol, and tofacitinib yielded no results and provide gap in research with a massive potential.

CONCLUSION
Combining newer therapies with conventional ones is a promising prospect to manage difficult to treat psoriasis. Combining drugs when suited to patients needs can enhance efficacy, achieve remission, while reducing adverse effects. With available evidence, there are limited options with highest level of evidence and hence recommendation. Due to a smaller number of studies in combination of drugs, research providing more high-quality evidence is required.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS
SA: conception and design, acquisition of data, literature search, analysis and interpretation of data, drafting the manuscript, and revising it. PD and GA: acquisition of data, literature search, analysis and interpretation of data, drafting the manuscript, and revising it. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. (2017) 31:205–12. doi: 10.1111/jdv.13854
2. Arora S, Jairam A, Radhakrishnan S, Das N, Vankalakunti M. PLA2R antibody positive membranous glomerulonephropathy associated with psoriasis vulgaris. Indian J Dermatol Venereol Leprol. (2019) 85:682. doi: 10.4103/ijvl.IJDVLC_298_18
3. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. (2018) 36:21–8. doi: 10.1016/j.clindermatol.2017.09.005
4. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. J Am Acad Dermatol. (2017) 77:657–66.e8. doi: 10.1016/j.jaad.2017.04.1133
5. Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. (2015) 73:242–8. doi: 10.1016/j.jaad.2015.05.001
6. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaran A, Gladman DD. Patients with psoriatic arthropathies have worse quality of life than those with psoriasis alone. Rheumatol Ost Engel. (2012) 51:571–6. doi: 10.1093/rheumatology/ker365
7. Rech J, Sticherling M, Stoessel D, Biermann MHC, Härberle BM, Reinhardt M. Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis. Rheumatol Adv Pract. (2020) 4:kaa033. doi: 10.1093/rap/kaa033
8. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. (1990) 17:809–12.
9. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. (2014) 13:490–5. doi: 10.1016/j.autrev.2014.01.008
10. Heller MM, Wong JW, Nguyen TV, Lee ES, Bhutani T, Menter A, et al. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin. (2012) 30:281–91, ix. doi: 10.1016/j.det.2011.11.006
11. Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis. Available online at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486272/ (accessed April 9, 2021).
12. Polat Ekinci A, Bölük KN, Babuna Kobaner G. Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: a case series of high efficacy and safety profile. Dermatol Ther. (2020) e14704. doi: 10.1111/dth.14704
13. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician Med Fam Can. (2017) 65:728–85.
14. Renhold K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. (2017) 18:2297. doi: 10.3390/ijms18112297
15. Tanew A, Guggenbihler A, Hönigsmann H, Geiger JM, Fritsch P. Photothermodermography for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. (1991) 25:687–688. doi: 10.1016/0190-9622(91)72023-3
16. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. (1991) 24:591–4. doi: 10.1016/0190-9622(91)70089-K
17. Lynde CW, Gupta AK, Guenther L, Poulin Y, Levesque A, Bissonnette R. A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept. J Dermatol Treat. (2012) 23:261–7. doi: 10.3109/09546634.2011.607795
18. Park KK, Wu JJ, Koo J. A randomized, “head-to-head” pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol. (2013) 27:899–906. doi: 10.1111/j.1468-3083.2012.04611.x
19. Calzavara-Pinton PG, Sala R, Arisi M, Rossi MT, Venturini M, Ortel B. Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis. Br J Dermatol. (2013) 169:130–6. doi: 10.1111/bjd.12277
20. Gambichler T, Tigges C, Scola N, Weber J, Strygman M, Bechara FG, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol. (2011) 164:1383–6. doi: 10.1111/j.1365-2133.2011.10358.x
21. Wolf P, Weger W, Legat FJ, Posch-Fabian T, Gruber-Wackernagel A, Inzinger M, et al. Treatment with 311-nm ultraviolet B-enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intrapatiental trial. Br J Dermatol. (2012) 166:147–53. doi: 10.1111/j.1365-2133.2011.10616.x
22. Mahajan R, Kaur I, Kanwar AJ. Methotrexate/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis—a randomized single-blinded placebo-controlled study. J Eur Acad Dermatol Venereol. (2010) 24:595–600. doi: 10.1111/j.1468-3083.2009.03486.x
23. Asawamonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment
of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol. (2006) 54:1013–8. doi: 10.1016/j.jaad.2006.01.004
24. Al-Hamamy HR, Al-Mashhadani SA, Mustafa IN. Comparative study of the effect of narrowband ultraviolet B phototherapy plus methotrexate vs. narrowband ultraviolet B alone and methotrexate alone in the treatment of plaque-type psoriasis. Int J Dermatol. (2014) 53:1531–5. doi: 10.1111/ijd.12444
25. Zachariae C, Mørk NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. (2008) 88:495–501. doi: 10.2340/00015555-0511
26. Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. (2012) 167:649–57. doi: 10.1111/j.1365-2133.2012.11015.x
27. Yu Q, Tong Y, Cui L, Zhang L, Gong Y, Diao H, et al. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis. Int Immunopharmacol. (2019) 73:442–50. doi: 10.1016/j.intimp.2019.05.057
28. Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Hellwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol Hoboken NJ. (2011) 71:1112–24. doi: 10.1002/art.40851
29. Baranaukaite A, Raffayová H, Kungurov NV, Kubanova A, Venalis A, Helmel L, et al. Indinavir plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthropathies in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. (2012) 71:541–8. doi: 10.1136/ard.2011.152223
30. van Mens LJJ, de Jong HM, Fluri I, Nurmoohamed MT, van de Sande MGH, Kok M, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. (2019) 78:610–6. doi: 10.1136/annrheumdis-2018-214746
31. Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardino A, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOLimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. (2020) 79:690–8. doi: 10.1136/annrheumdis-2019-216500
32. Lee JH, Youn JI, Kim TY, Choi JH, Park CJ, Choe YB, et al. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. BMC Dermatol. (2016) 16:11. doi: 10.1186/s12895-016-0048-2
33. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. (2008) 158:1345–9. doi: 10.1111/j.1365-2133.2008.08564.x
34. van Bezooinen JS, Balak DM, van Doorn MB, Looman CW, Schreurs MW, Koch BC, et al. Combination therapy of etanercept and fumarates versus etanercept monotherapy in psoriasis: a randomized exploratory study. Dermatol Basel Switz. (2016) 232:407–14. doi: 10.1159/000448135
35. Tzanova S, Geroldinger A, Trattner H, Tanew A. Fumaric acid esters in patients with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study. Br J Dermatol. (2018) 178:682–8. doi: 10.1111/bjd.16106
36. Prystowsky JH, Muzio PJ, Sevran S, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris—Update 2015–Short version–EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. (2015) 29:2277–94. doi: 10.1111/jdv.13354
37. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. (2014) 170:261–73. doi: 10.1111/bjd.12654
38. Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept in a single centre, cohort study. Br J Dermatol. (2013) 169:306–13. doi: 10.1111/bjd.12341
39. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept
twice weekly in patients with psoriasis. Arch Dermatol. (2007) 143:719–26. doi: 10.1001/archderm.143.6.719
59. Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol. (2012) 67:642–50. doi: 10.1016/j.jaad.2011.10.020
60. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. (2007) 56:31.e1–15. doi: 10.1016/j.jaad.2006.07.017
61. Aşıroğlu E, Aral A, Aybay C, Gürel MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol. (2010) 37:708–13. doi: 10.1111/j.1346-8138.2010.00882.x
62. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. (2010) 362:118–28. doi: 10.1056/NEJMoat0810652
63. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet Lond Engl. (2008) 371:1675–84. doi: 10.1016/S0140-6736(08)60726-6
64. Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis. (2011) 70:712–4. doi: 10.1136/ard.2010.130864
65. Metras S, Tomassian C, Messiah R, Gettas T, Chen C, Quismorio A. Combination therapy of apremilast and biologic agent as a safe option of psoriatic arthritis and psoriasis. Curr Rheumatol Rev. (2019) 15:234–7. doi: 10.2174/1573397115666181130094455
66. Takamura S, Sugai S, Taguchi R, Teraki Y. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue. J Dermatol. (2020) 47:290–4. doi: 10.1111/1346-8138.15193
67. AbuHilal M, Walsh S, Shear N. Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg. (2016) 20:313–6. doi: 10.1177/1203475416631328
68. Lee ES, Heller MM, Kamangar F, Park K, Liao W, Koo J. Hydroxyurea for the treatment of psoriasis including in HIV-infected individuals: a review. Psoriasis Forum. (2011) 17:180–7. doi: 10.1177/247553031172083020
69. Lori E, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. (1994) 266:801–5. doi: 10.1126/science.73634
70. Salmon-Ehr V, Grosieux C, Potron G, Kalis B. Multiple actinic keratoses and skin tumors secondary to hydroxyurea treatment. Dermatol Basel Switz. (1998) 196:274.
71. Sauer GC. Combined methotrexate and hydroxyurea therapy for psoriasis. Arch Dermatol. (1973) 107:369–70. doi: 10.1001/archderm.107.3.369

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Arora, Das and Arora. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.